Dosimetric quality and acute toxicity in HDR-brachytherapy as monotherapy in low risk prostate cancer

被引：0
|
作者：
Isaak, B [1 ]
Thalmann, G [1 ]
Vock, J [1 ]
Rentsch, CA [1 ]
Manser, P [1 ]
Mini, R [1 ]
Greiner, RH [1 ]
Kolotas, C [1 ]
Aebersold, D [1 ]
机构：
[1] Univ Bern, Dept Radiat Oncol, Inselspital, Bern, Switzerland
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2005年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [31] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [32] Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer
    Hasan, Y.
    Loblaw, D. A.
    Chung, H. R.
    McGuffin, M.
    Tseng, C. L.
    Mendez, L. C.
    Ravi, A.
    Zhang, L.
    Mamedov, A.
    Morton, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S133 - S133
  • [33] TOXICITY AND QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE II TRIAL OF HDR MONOTHERAPY FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER
    Hasan, Yaser
    Loblaw, Andrew
    Chung, Hans
    McGuffin, Merrylee
    Tseng, Chia-Lin
    Mendez, Lucas
    Ravi, Ananth
    Zhang, Liying
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S36 - S36
  • [34] Interstitial HDR-brachytherapy (BT) in patients with lip cancer
    Friedrich, E. E.
    Behrensmeier, F.
    Isaak, B.
    Greiner, R. H.
    Kolotas, C.
    Aebersold, D. M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 175 - 175
  • [35] THE INFLUENCE OF DOSIMETRY ON ACUTE URINARY TOXICITY IN HDR PROSTATE BRACHYTHERAPY
    El-Bared, Nancy
    Desrashodian, Talar
    Wakil, Georges
    Mondat, Marise
    Berbiche, Djamal
    Jolicoeur, Marjorie
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S53 - S53
  • [36] The effect of catheter displacement on acute and late toxicity in fractionated HDR monotherapy of prostate cancer
    Aluwini, S.
    Bhawanie, A.
    Baartman, L.
    Alemayehu, W. Ghidey
    Busser, W.
    Boormans, J.
    Kolkman-Deurloo, I. K.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S17 - S18
  • [37] Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer
    Diez, Patricia
    Mullassery, Vinod
    Dankulchai, Pittaya
    Ostler, Peter
    Hughes, Robert
    Alonzi, Roberto
    Lowe, Gerry
    Hoskin, Peter J.
    RADIOTHERAPY AND ONCOLOGY, 2014, 113 (03) : 410 - 413
  • [38] Late sequelae in 400 prostate cancer patients treated with combined EBRT and HDR-brachytherapy
    Boehmer, D
    Deger, S
    Dinges, S
    Loening, SA
    Budach, V
    PROGRESS IN RADIO-ONCOLOGY VII, PROCEEDINGS, 2001, : 731 - 732
  • [39] HDR-brachytherapy or SBRT for extreme hypofractionation in prostate cancer - long-term results
    Aluwini, S.
    Busser, W.
    Kroon, M.
    Heijmen, B.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S386 - S387
  • [40] Follow-up-Studies with combined Telephone-/HDR-Brachytherapy of Prostate Cancer
    Siebert, F-A
    Juergens, L.
    Bockelmann, G.
    Jiang, P.
    Nuernberg, N.
    Dunst, J.
    Schultze, J.
    Galalae, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 : S56 - S57
12345